LEADER 02314nam  2200457z- 450 
001 9910136792003321
005 20210211
035   $a(CKB)3710000000631061
035   $a(oapen)https://directory.doabooks.org/handle/20.500.12854/55432
035   $a(oapen)doab55432
035   $a(EXLCZ)993710000000631061
100   $a20202102d2015      |y         0
101 0 $aeng
135   $aurmn|---annan
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aThe Origin of the Plasma Cell Heterogeneity
210   $cFrontiers Media SA$d2015
215   $a1 online resource (80 p.)
225 1 $aFrontiers Research Topics
311 08$a9782889197347 
311 08$a2889197344 
330   $aPlasma cells (PCs) are terminally differentiated B-cells producing large amounts of immunoglobulins (Ig). In humans, most of circulating Ig are produced by bone marrow plasma cells. PCs differentiate from activated nai?ve or memory B-cells usually activated by specific antigens. It is still controversial whether the regulation of PCs numbers and the "active" in vivo Ig diversity depend or not on non-specific reactivation of B-cells during infections. Depending on the stimulus (T-independent/T-dependent antigen, cytokines, partner cells) and B-cell types (nai?ve or memory, circulating or germinal center, lymph nodes or spleen, B1 or B2...), both the phenotype and isotype of PCs differ suggesting that PC diversity is either linked to B-cell diversity or to the type of stimulus or to both. Knowledge of the mechanisms supporting PC diversity has important consequences for the management of i) plasma cell neoplasia such as Multiple Myeloma and Waldenstro?m's Macroglobulinemia, ii) vaccine protection against pathogens and iii) auto-immune diseases.
606   $aMedicine$2bicssc
610   $aAutoimmunity
610   $aAutophagy
610   $aB-cell
610   $aB1
610   $aCell Cycle
610   $adifferentiation
610   $aIL21
610   $aMyeloma
610   $aPlasma cell
615  7$aMedicine
700   $aDefrance$b Thierry$4auth$01837976
702   $aPellat-Deceunynck$b Catherine$4auth
906   $aBOOK
912   $a9910136792003321
996   $aThe Origin of the Plasma Cell Heterogeneity$94416852
997   $aUNINA